XOMA Corporation files for an $86 million Initial Public Offering (IPO).
The company plans to use the proceeds to advance its antibody-based therapeutics through clinical trials.
XOMA's pipeline targets inflammatory and autoimmune diseases, including Type 1 diabetes and osteoarthritis.
👉 Read the full institutional analysis, options flow, and live charts on BuzzTickr.com »
Top comments (0)